Iranian COVID-19 Drug Remdesivir to be Mass-Produced

Saturday, July 25, 2020 - 12:29

The CEO of an Iranian Pharmaceutical public company, as one of the largest pharmaceutical holding Companies and knowledge-based economical complex in Iran, has announced on mass production of Iranian Remdesivir to prevent many COVID-19 deaths in the country.

According to an ISCA report, Akbar Borandegi, CEO of Barkat Pharmaceutical Group, explained that Remdesivir is an investigational new drug created by Gilead, appeared to help COVID-19 patients recover faster. That earned remdesivir an emergency use authorization (EUA) from the FDA, allowing it to be used more broadly outside of clinical trials.

Borandegi noted that after finishing clinical trials, this drug will be mass-produced and enter the market with reasonable price, "we have cooperated with an Indian company and worked on the formula mutually in order to save more time."

He went on to note that the drug is effective for patients with confirmed COVID-19 infection who are in moderate stage of that. As he said, besides supplying domestic needs, we are also making efforts to export this drug to the neighboring countries.

Remdesivir was studied in clinical trials for Ebola virus infections but showed limited benefit. Remdesivir has been shown to inhibit replication of other human coronaviruses associated with high morbidity in tissue cultures, including severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012.


Popular News

Latest News